Valiant Laboratories

Valiant Laboratories Equity Ratio

The Equity Ratio of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 67.00 %. In the previous year, Equity Ratio was 58.45 % — a change of 14.63% (higher).

Equity Ratio

67.00 %

YoY

14.63%

Last updated:

Equity Ratio of Valiant Laboratories is 2026 67.00 % . Equity Ratio of Valiant Laboratories was 2025 58.45 % . It decreases by 14.63% higher compared to the previous year.

The Valiant Laboratories Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2021
83.32 INR
Jan 1, 2022
39.30 INR
Jan 1, 2023
47.19 INR
Jan 1, 2024
69.12 INR
Jan 1, 2025
58.45 INR
Jan 1, 2026
67.00 INR
The Valiant Laboratories Equity Ratio history
YEAREquity RatioYoY
67.00 %+14.63%
58.45 %-15.43%
69.12 %+46.48%
47.19 %+20.05%
39.30 %-52.83%
83.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Equity Ratio of Valiant Laboratories is 67.00 % in 2026.

Equity Ratio of Valiant Laboratories changed from 58.45 % to 67.00 %, representing a 14.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Valiant Laboratories

All Key Metrics — Valiant Laboratories